Dr Jessica Baker Flechtner | Chief Scientific Officer
Genocea Biosciences, Inc.

Dr Jessica Baker Flechtner, Chief Scientific Officer, Genocea Biosciences, Inc.

Jessica Baker Flechtner, Ph.D. joined Genocea Biosciences in 2007, soon after the company was founded, and currently serves as the senior vice president of Research. Dr. Flechtner is a pioneer in the development of novel vaccines directed toward T cell immunity, and has more than 20 years of experience in immunology, infectious disease, cancer, and vaccine development.  She leads Genocea’s efforts to develop T cell-directed vaccines and immunotherapies against infectious diseases and cancer. Prior to joining Genocea, Dr. Flechtner developed vaccines and immunotherapies for cancer, infectious disease, autoimmunity and allergy in several companies including Mojave Therapeutics and Antigenics Inc. (now Agenus). She is an inventor on multiple issued and pending patents. Dr. Flechtner performed her post-doctoral work at the Dana Farber Cancer Institute and Harvard Medical School. She holds a Ph.D. in Cellular Immunology and a B.S. in Animal Science from Cornell University, and is a member of the American Association of Immunologists and American Society for Microbiology.

Appearances:



Agenda Day 1 @ 11:45

Personalized cancer vaccines that target patients-specific mutations: Platforms amenable for neoantigen vaccination

  • Strategies for target antigen identification and validation 
  • Personalized vaccines-specific considerations in adjuvant selection
  • Challenges in clinical studies, i.e., patient selection, dose selection, efficacy determination and regulatory paths

back to speakers